4-154568456-C-T

Variant summary

Our verdict is Benign. The variant received -7 ACMG points: 2P and 9B. PM1BP4_StrongBS1_SupportingBS2

The NM_005141.5(FGB):​c.794C>T​(p.Pro265Leu) variant causes a missense change. The variant allele was found at a frequency of 0.00425 in 1,597,176 control chromosomes in the GnomAD database, including 20 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.0028 ( 0 hom., cov: 31)
Exomes 𝑓: 0.0044 ( 20 hom. )

Consequence

FGB
NM_005141.5 missense

Scores

4
10
5

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications P:2U:10B:2

Conservation

PhyloP100: 5.90

Publications

25 publications found
Variant links:
Genes affected
FGB (HGNC:3662): (fibrinogen beta chain) The protein encoded by this gene is the beta component of fibrinogen, a blood-borne glycoprotein comprised of three pairs of nonidentical polypeptide chains. Following vascular injury, fibrinogen is cleaved by thrombin to form fibrin which is the most abundant component of blood clots. In addition, various cleavage products of fibrinogen and fibrin regulate cell adhesion and spreading, display vasoconstrictor and chemotactic activities, and are mitogens for several cell types. Fibrinogen serves key roles in hemostasis and antimicrobial host defense. Mutations in this gene lead to several disorders, including afibrinogenemia, dysfibrinogenemia, hypodysfibrinogenemia and thrombotic tendency. [provided by RefSeq, Aug 2020]
FGB Gene-Disease associations (from GenCC):
  • congenital fibrinogen deficiency
    Inheritance: SD Classification: DEFINITIVE Submitted by: ClinGen
  • thrombophilia
    Inheritance: AD, AR Classification: STRONG Submitted by: Genomics England PanelApp
  • congenital afibrinogenemia
    Inheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae)
  • familial dysfibrinogenemia
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • familial hypofibrinogenemia
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -7 ACMG points.

PM1
In a domain Fibrinogen C-terminal (size 256) in uniprot entity FIBB_HUMAN there are 4 pathogenic changes around while only 1 benign (80%) in NM_005141.5
BP4
Computational evidence support a benign effect (MetaRNN=0.045531124).
BS1
Variant frequency is greater than expected in population nfe. GnomAd4 allele frequency = 0.00276 (419/152052) while in subpopulation NFE AF = 0.00512 (348/67988). AF 95% confidence interval is 0.00468. There are 0 homozygotes in GnomAd4. There are 163 alleles in the male GnomAd4 subpopulation. Median coverage is 31. This position passed quality control check. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
BS2
High Homozygotes in GnomAdExome4 at 20 SD,AD,AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
FGBNM_005141.5 linkc.794C>T p.Pro265Leu missense_variant Exon 5 of 8 ENST00000302068.9 NP_005132.2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
FGBENST00000302068.9 linkc.794C>T p.Pro265Leu missense_variant Exon 5 of 8 1 NM_005141.5 ENSP00000306099.4
FGBENST00000509493.1 linkc.137C>T p.Pro46Leu missense_variant Exon 3 of 6 5 ENSP00000426757.1
FGBENST00000502545.5 linkn.775C>T non_coding_transcript_exon_variant Exon 5 of 7 5

Frequencies

GnomAD3 genomes
AF:
0.00276
AC:
419
AN:
151936
Hom.:
0
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.00114
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000656
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.000771
Gnomad SAS
AF:
0.00104
Gnomad FIN
AF:
0.0000946
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00512
Gnomad OTH
AF:
0.00192
GnomAD2 exomes
AF:
0.00235
AC:
591
AN:
251290
AF XY:
0.00242
show subpopulations
Gnomad AFR exome
AF:
0.000738
Gnomad AMR exome
AF:
0.000405
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.000598
Gnomad FIN exome
AF:
0.000278
Gnomad NFE exome
AF:
0.00443
Gnomad OTH exome
AF:
0.00163
GnomAD4 exome
AF:
0.00441
AC:
6373
AN:
1445124
Hom.:
20
Cov.:
27
AF XY:
0.00426
AC XY:
3067
AN XY:
720022
show subpopulations
African (AFR)
AF:
0.000512
AC:
17
AN:
33190
American (AMR)
AF:
0.000514
AC:
23
AN:
44706
Ashkenazi Jewish (ASJ)
AF:
0.0000384
AC:
1
AN:
26036
East Asian (EAS)
AF:
0.000858
AC:
34
AN:
39614
South Asian (SAS)
AF:
0.000896
AC:
77
AN:
85904
European-Finnish (FIN)
AF:
0.000319
AC:
17
AN:
53338
Middle Eastern (MID)
AF:
0.000873
AC:
5
AN:
5726
European-Non Finnish (NFE)
AF:
0.00547
AC:
6003
AN:
1096726
Other (OTH)
AF:
0.00327
AC:
196
AN:
59884
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.450
Heterozygous variant carriers
0
259
519
778
1038
1297
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
228
456
684
912
1140
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00276
AC:
419
AN:
152052
Hom.:
0
Cov.:
31
AF XY:
0.00219
AC XY:
163
AN XY:
74310
show subpopulations
African (AFR)
AF:
0.00113
AC:
47
AN:
41470
American (AMR)
AF:
0.000655
AC:
10
AN:
15258
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3464
East Asian (EAS)
AF:
0.000772
AC:
4
AN:
5178
South Asian (SAS)
AF:
0.00104
AC:
5
AN:
4806
European-Finnish (FIN)
AF:
0.0000946
AC:
1
AN:
10574
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.00512
AC:
348
AN:
67988
Other (OTH)
AF:
0.00190
AC:
4
AN:
2108
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.505
Heterozygous variant carriers
0
23
47
70
94
117
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00392
Hom.:
8
Bravo
AF:
0.00248
TwinsUK
AF:
0.00674
AC:
25
ALSPAC
AF:
0.00571
AC:
22
ESP6500AA
AF:
0.00136
AC:
6
ESP6500EA
AF:
0.00407
AC:
35
ExAC
AF:
0.00243
AC:
295
Asia WGS
AF:
0.000289
AC:
1
AN:
3478
EpiCase
AF:
0.00420
EpiControl
AF:
0.00421

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:2Uncertain:10Benign:2
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Uncertain:2Benign:1
-
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Jan 26, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Congenital afibrinogenemia Pathogenic:1Uncertain:1
Aug 18, 2023
Department of Pathology and Laboratory Medicine, Sinai Health System
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:research

- -

Jun 01, 2017
Mayo Clinic Laboratories, Mayo Clinic
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Uncertain:1Benign:1
Jan 20, 2025
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: FGB c.794C>T (p.Pro265Leu) results in a non-conservative amino acid change located in the C-terminal globular domain (IPR002181) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0024 in 251290 control chromosomes, predominantly at a frequency of 0.0044 within the Non-Finnish European subpopulation in the gnomAD database. The observed variant frequency within Non-Finnish European control individuals in the gnomAD database exceeds the estimated maximal expected allele frequency for a pathogenic variant in FGB causing Afibrinogenemia, Congenital phenotype. c.794C>T has been reported in several heterozygous individuals affected with hypofibrinogenemia and various (suspected) bleeding/coagulation disorders (Brennan_2000, Morris_2009, Downes_2019, Almazni_2020, Preisler_2020). Large scale population studies demonstrated an association with slightly lower (~10%) fibrinogen levels (Wassel_2010, Huffman_2015, de Vries_2016). In addition, at least one publication reported experimental evidence evaluating an impact on protein function, and demonstrated decreased clot formation and clot lysis in heterozygous patient samples, which corresponded to about 70% of the control values (Morris_2009). The following publications have been ascertained in the context of this evaluation (PMID: 31064749, 32935436, 10688828, 33477601, 26105150, 19420351, 20978265, 26561523). ClinVar contains an entry for this variant (Variation ID: 517313). Based on the evidence outlined above, the variant was classified as likely benign. -

Mar 28, 2017
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant classified as Uncertain Significance - Favor Benign. The p.Pro265Leu (NM _005141.4 c.794C>T) variant in FGB has been reported in 3 compound heterozygous and 1 homozygous individuals with Hypofibrinogenemia or Chronic thromboembolic p ulmonary hypertension (CTEPH), though the additional variants found in heterozyg osity were not well-established pathogenic variants (Brennan 2000 and Morris 200 9). In vitro functional studies provide conflicting data (Brennan 2000 and Morri s 2009). This variant has been identified in 0.381% (254/66716) of European chro mosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.or g; dbSNP rs52828882, rs2227436, rs6054) as well as 5% of controls in the Brennan 2000 study. In summary, the clinical significance of the p.Pro265Leu variant is uncertain; however, based on population frequency and functional data we favor a benign interpretation. -

Abnormal bleeding Pathogenic:1
Feb 01, 2019
NIHR Bioresource Rare Diseases, University of Cambridge
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:research

- -

Thrombus Uncertain:1
-
ISTH-SSC Genomics in Thrombosis and Hemostasis, KU Leuven, Center for Molecular and Vascular Biology
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

FGB-related disorder Uncertain:1
Jun 17, 2024
PreventionGenetics, part of Exact Sciences
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:clinical testing

The FGB c.794C>T variant is predicted to result in the amino acid substitution p.Pro265Leu. This variant, also described using legacy nomenclature as p.Pro235Leu, has been reported in individuals with hypofibrinogenemia, chronic thromboembolic pulmonary hypertension, or platelet defect (Brennan et al. 2000. PubMed ID: 10688828; Morris et al. 2009. PubMed ID: 19420351; Almazni et al. 2020. PubMed ID: 32935436). However, this variant has also been reported in healthy controls (Brennan et al. 2000. PubMed ID: 10688828). This variant is reported in 0.44% of alleles in individuals of European (Non-Finnish) descent in gnomAD. In ClinVar, this variant has conflicting interpretations of likely benign, uncertain significance, likely pathogenic, and pathogenic (https://www.ncbi.nlm.nih.gov/clinvar/variation/517313/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -

Thrombocytopenia;C1458140:Abnormal bleeding Uncertain:1
May 01, 2020
Birmingham Platelet Group; University of Birmingham
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:research

- -

Hypofibrinogenemia Uncertain:1
Feb 01, 2019
NIHR Bioresource Rare Diseases, University of Cambridge
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:research

- -

Familial dysfibrinogenemia Uncertain:1
-
ISTH-SSC Genomics in Thrombosis and Hemostasis, KU Leuven, Center for Molecular and Vascular Biology
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Afibrinogenemia Uncertain:1
-
ISTH-SSC Genomics in Thrombosis and Hemostasis, KU Leuven, Center for Molecular and Vascular Biology
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.28
BayesDel_addAF
Uncertain
0.045
T
BayesDel_noAF
Pathogenic
0.30
CADD
Uncertain
25
DANN
Uncertain
0.99
DEOGEN2
Benign
0.24
T;.
Eigen
Pathogenic
0.69
Eigen_PC
Uncertain
0.61
FATHMM_MKL
Pathogenic
0.99
D
LIST_S2
Uncertain
0.93
D;D
M_CAP
Uncertain
0.21
D
MetaRNN
Benign
0.046
T;T
MetaSVM
Uncertain
0.50
D
MutationAssessor
Uncertain
2.5
M;.
PhyloP100
5.9
PrimateAI
Uncertain
0.56
T
PROVEAN
Pathogenic
-5.6
D;D
REVEL
Uncertain
0.57
Sift
Uncertain
0.011
D;T
Sift4G
Benign
0.099
T;T
Polyphen
1.0
D;.
Vest4
0.82
MVP
0.97
MPC
0.70
ClinPred
0.058
T
GERP RS
5.8
Varity_R
0.58
gMVP
0.86
Mutation Taster
=9/91
disease causing (ClinVar)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs6054; hg19: chr4-155489608; API